CLARITY

Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease

Issue 4 | 07 September 2020

Study Overview

CLARITY will establish whether Angiotensin Receptor Blockers (ARBs) can reduce the severity of COVID-19. Pragmatic trial design embedded in routine care to avoid placing additional demands on busy health staff.

Progress Updates

India

- IMP labelled in double-blind format packaged and shipped to initiated sites.
- 4 sites initiated, undergoing set up (AIIMS, Raipur, CMC, Ludhiana, Christian Hospital, Nabarangpur & LNJP, Delhi).





Australia

- 1 participant randomised (RPA Hospital).
- 8 sites activated (Canterbury, Concord, RPA, RNSH, Wollongong, St George, Austin & Prince of Wales Hospitals).
- 7 sites initiated, undergoing set up (RPA Virtual, John Hunter, Westmead, Liverpool, Alfred, Sutherland & Sunshine Hospitals).

Meet the Research Fellows



Dr Sradha Kotwal – CLARITY Co-Scientific Lead & Study Physician

Sradha is a nephrologist at Prince of Wales in Sydney, a research fellow at

TGI Australia and a conjoint senior lecturer at UNSW. She has expertise in
implementation research, translation of research into practice and linked data.



Mr Abhinav Basso – CLARITY Research Fellow

Abhinav is a physiotherapist trained in public health, currently working as a Research Fellow at the George Institute for Global Health, India. Diabetes, CKD and mobile health interventions are key areas of his work.



Dr Carinna Hockham – CLARITY Co-Scientific Lead

Carinna is a research fellow at TGI Australia and Conjoint Lecturer at UNSW.

Carinna's research involves using novel trial methodologies, including adaptive design, to improve health outcomes in people with chronic disease.


Relevant Literature Updates

BRACE CORONA

- Trial conducted in Brazil.
- Randomised 659 COVID-19 patients already treated with an ARB/ACEI to either suspend their RAASi treatment or continue their RAASi treatment.
- · Relatively young and low-risk cohort with low event rate
- No difference in Days Alive and Out of Hospital at 30 days between the two arms or in all-cause mortality at 30 days.

Online Training Modules

Click the pictures below to be directed to CLARITY's training modules. These include Background & Rationale, ARB Guidance and Operations.







'Endpoint & Trial Design' training module coming soon!

Project Timelines

MAR 2020	Protocol Development	Done
MAY 2020	Study Set up Activities	Done
JUN 2020	First Site Activated	Done
	MRFF Funding Received	
AUG 2020	First Participant First Visit	Done
SEP 2020	All Sites Activated – India & Australia	
	DSMB #1	
DEC 2020	Last Participant First Visit	
JAN 2021	All Primary Outcome Data	
	Primary Analysis & Publication	
	Last Participant Last Visit	
MAR 2021	Database Lock & All Sites Closed	
	Secondary Analyses & Publication	

